Managing Sunscreen SPF in Australia

Regulatory Oversight, SPF Compliance and Lessons for Industry

Australia relies on sunscreen more than most countries. Yet in 2025, a wave of reporting and consumer testing challenged a core assumption that the SPF printed on the label consistently reflects the protection delivered in real-world products.

CHOICE testing reported that 16 of 20 sunscreens did not meet their stated SPF claims, including one product that tested as low as SPF 4 despite being marketed as SPF 50+. Those results have triggered recalls and supply pauses, intensified media scrutiny, and prompted the Therapeutic Goods Administration (TGA) to open an 8‑week public consultation in March 2026 on improving sunscreen regulation.

For therapeutic goods manufacturers, this is more than a consumer story. It is a case study in how variability in testing, scale-up decisions, contract laboratory oversight and lifecycle quality systems can converge to create regulatory and reputational risk. This blog reviews the management of sunscreens in Australia, key lessons from the SPF ‘failures’ story, and the practical implications of the TGA’s proposed reforms for sponsors and manufacturers.

How sunscreens are regulated in Australia

Unlike many international markets where sunscreens are treated as cosmetics, Australia’s therapeutic goods framework reflects the critical health role sunscreens play in preventing skin cancer.

When sunscreens make therapeutic claims about sun protection, the TGA is responsible for their regulation as therapeutic goods. Most therapeutic sunscreens are ‘listed’ in the Australian Register of Therapeutic Goods (ARTG). This means that Sponsors must certify that the product meets applicable quality, safety and efficacy requirements, and uses only approved ingredients and indications. However, some combination products (e.g. moisturisers with SPF claims) may be regulated as cosmetics if they meet specific criteria.

This framework keeps effective sunscreens accessible to consumers while enabling the regulator to focus resources on post‑market surveillance, targeted compliance reviews and recalls. In practice, it places strong accountability on sponsors and manufacturers to ensure that:

• they support SPF and label claims with robust evidence
• the marketed formulation is representative of the tested formulation
• they control and validate manufacturing changes
• quality systems detect drift over time (e.g., raw material variability, equipment differences, process changes)

The recent SPF controversy has shown that ‘listing’ pathways still demand rigorous GMP (Good Manufacturing Practice) discipline, especially for products that sit at the boundary between cosmetic positioning and therapeutic claims.

What the sunscreen SPF failures revealed: testing variability and lifecycle gaps

The media reported on sunscreen performance, with the story being fuelled by two linked themes:

(1) variability in SPF test outcomes, and

(2) concerns that some evidence used to justify SPF claims may not be reliable or representative.

• CHOICE’s 2025 investigation reported widespread shortfalls against labelled SPF, with some products returning results in the 20s and 30s despite the label claim being SPF 50+.
• Some test results fell in the 20s and 30s despite the label claim being SPF 50+
• The ABC later reported on broader concerns around the SPF testing ecosystem and product supply models.
• By March 2026, dozens of products had been pulled from shelves or paused from supply, with the TGA citing the need to improve reliability and transparency of SPF testing and strengthen oversight of testing laboratories.

From a quality perspective, the story highlights several product lifecycle failures that are familiar across therapeutic goods manufacturing:

• Evidence that is not representative of the final product: SPF data may be generated on a pilot batch, base formulation, or earlier formulation version. If the commercial scale‑up alters critical quality attributes (e.g., particle dispersion, film formation, emulsion stability), the marketed product can perform differently.
• Contract laboratory risk: If SPF evidence relies heavily on third‑party laboratories, sponsors need data integrity assurance, method validation confidence and appropriate qualification. Weak laboratory governance can introduce variability or unreliable results.
• Change control discipline: Sunscreens are formulation‑sensitive products. Seemingly small changes, such as supplier changes, preservative systems, mixing energy, fill‑finish parameters, may impact SPF performance. A risk‑based change control system is essential to decide when confirmatory SPF testing is required.

Why sunscreen SPF testing can be difficult to reproduce

Historically, SPF testing has relied on in vivo methods, where sunscreen is applied to human volunteers and the skin response to ultraviolet (UV) radiation is measured under controlled conditions. While internationally recognised, in vivo methods can show variability due to differences in skin type, application uniformity, test site preparation and environmental controls.

The TGA consultation materials acknowledge concerns about variability and reproducibility of current SPF testing methods, alongside questions about oversight of laboratories performing SPF testing. In response, the TGA is exploring options to improve reliability and transparency, and to enable newer testing technologies to be adopted more quickly.

Where newer in vitro methods are considered, sponsors should be cautious about scope (e.g., whether water resistance claims are supported) and ensure methods are aligned with the current regulatory position.

The TGA’s proposed reforms (March 2026): what’s on the table

On 26 March 2026, the TGA opened an 8‑week public consultation titled ‘Seeking improvements to the regulation of sunscreens in Australia’. The aim is to strengthen confidence in sunscreen performance in a country with very high skin cancer burden.

Key Issues Identified:

• Variability and reproducibility concerns with current SPF in vivo testing methods. ​
• Limited oversight of laboratories performing SPF testing. ​
• Lack of flexibility to adopt new international testing standards. ​
• Insufficient evidence requirements for SPF claims, often based on base formulations rather than finished products. ​
• Lack of transparency in SPF testing data for regulators and consumers. ​
• Potential efficacy and quality concerns with specific formulations and ingredients. ​
• Misleading SPF claims on cosmetic sunscreens. ​
• Outdated GMP guidance for sunscreen manufacturing.

To address these findings, the consultation proposes options across several focus areas, including:

• Improving reliability and transparency of SPF testing
• Enabling new testing technologies to be adopted in a timelier manner
• Strengthening oversight of testing laboratories
• Enhancing lifecycle quality assurance, including periodic testing and ingredient standards
• Simplifying and clarifying SPF labelling
• Providing greater consistency with the indications that therapeutic and cosmetic sunscreens can make
• Updating GMP guidance to improve manufacturing quality

What manufacturers and sponsors should do now (and why)

Even while consultation is ongoing, there are practical actions sponsors and manufacturers can take to reduce risk and prepare for tighter oversight. These actions are consistent with mature GMP and quality risk management.

Strengthen sunscreen SPF evidence governance

SPF testing must be conducted in accordance with recognised standards and laboratories with appropriate expertise.

• Action: Map each SPF and label claim to the exact study, batch, laboratory and method used.
• Reason: Clear traceability reduces the risk of relying on non‑representative data and supports rapid response if evidence is challenged.

Reassess what constitutes a representative sample after scale‑up

• Action: Define ‘representative batch’ criteria (equipment, mixing energy, fill conditions, raw material grades) and trigger confirmatory SPF testing where scale‑up changes and raw material variability could affect performance to account for worse-case scenarios not just idea conditions.
• Reason: Media‑reported SPF failures have often highlighted discrepancies between laboratory samples and products available on retail shelves. Many performance gaps emerge at commercial scale; proactive confirmation protects consumers and reduces recall risk.

Qualify and monitor contract testing laboratories

• Action: Use a risk‑based qualification programme (audit scope, data integrity assessment, method validation review, proficiency/round‑robin evidence where available).
• Reason: The consultation explicitly targets laboratory oversight; strong supplier governance demonstrates sponsor control of outsourced activities.

Embed sunscreen SPF into the Quality Management System

• Action: Include SPF performance as a critical attribute, such that it is considered in change control, deviation and complaint management, as well as periodic product quality review and stability testing.
• Reason: This creates a defensible, lifecycle approach aligned with the TGA’s direction toward enhanced quality assurance and periodic testing.

Review sunscreen SPF label claims for clarity and compliance

• Action: Ensure wording aligns with approved indications and that cosmetic positioning does not obscure therapeutic claims obligations. SPF and broad‑spectrum claims must be accurate, substantiated and not misleading. Claims such as “SPF 50+” carry high consumer expectations and regulatory risk.
• Reason: The TGA is seeking greater consistency between therapeutic and cosmetic sunscreen claims; clarity reduces regulatory ambiguity and consumer confusion.

Lifecycle Management: Beyond Initial Listing

One of the key lessons from past sunscreen failures is the importance of product lifecycle management. Compliance does not end once a product is listed on the Australian Register of Therapeutic Goods (ARTG).

Effective lifecycle management includes:

• Periodic review of critical quality attributes
• Re‑testing when significant changes occur
• Proactive risk assessments aligned with ICH quality principles

This lifecycle approach is consistent with broader trends across therapeutic goods regulation and aligns closely with expectations for medicines and medical devices.

Post‑Market Monitoring and Vigilance

The TGA expects sponsors to actively monitor product performance once on the market. This includes:

• Reviewing consumer complaints related to sunburn or lack of efficacy
• Investigating trends that may indicate batch variability
• Notifying the TGA of significant quality or safety concerns

Why this matters: Post‑market surveillance is increasingly seen as a shared responsibility between regulator and sponsor.

PharmOut Services & Training

PharmOut supports therapeutic goods sponsors and manufacturers to strengthen regulatory compliance and GMP systems for performance‑critical products such as sunscreens. Our consultants can help you:

• implement risk‑based change control and validation aligned to formulation‑sensitive products
• qualify and govern contract testing laboratories, including data integrity and method oversight
• design lifecycle quality assurance programmes (e.g., periodic verification testing strategies)
• prepare for TGA inspections and respond to compliance reviews or recalls.

We also deliver targeted GMP training and workshops to help you ensure regulatory changes translate into practical, compliant process and procedural updates. Explore elearning and public courses via onlinegmptraining.com, or contact us via the website or via email to tailor workshops to your needs.

Frequently Asked Questions (FAQ)